Quidelortho Corp
F:QL1A

Watchlist Manager
Quidelortho Corp Logo
Quidelortho Corp
F:QL1A
Watchlist
Price: 10.215 EUR 3.68% Market Closed
Market Cap: €684.1m

Quidelortho Corp
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Quidelortho Corp
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Quidelortho Corp
F:QL1A
Net Issuance of Common Stock
$6.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Net Issuance of Common Stock
$282m
CAGR 3-Years
24%
CAGR 5-Years
-28%
CAGR 10-Years
12%
Edwards Lifesciences Corp
NYSE:EW
Net Issuance of Common Stock
-$719.3m
CAGR 3-Years
20%
CAGR 5-Years
-33%
CAGR 10-Years
-5%
Stryker Corp
NYSE:SYK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Net Issuance of Common Stock
-$497m
CAGR 3-Years
36%
CAGR 5-Years
-20%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Issuance of Common Stock
-$1.9B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Quidelortho Corp
Glance View

Market Cap
684.1m EUR
Industry
Health Care

QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.

QL1A Intrinsic Value
44.845 EUR
Undervaluation 77%
Intrinsic Value
Price €10.215

See Also

What is Quidelortho Corp's Net Issuance of Common Stock?
Net Issuance of Common Stock
6.1m USD

Based on the financial report for Dec 28, 2025, Quidelortho Corp's Net Issuance of Common Stock amounts to 6.1m USD.

What is Quidelortho Corp's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
22%

Over the last year, the Net Issuance of Common Stock growth was 22%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett